Current Controversy and Developments Regarding the Cytoreductive Prostatectomy for Oligometastatic Prostate Cancer
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231216011. doi: 10.1177/15330338231216011.ABSTRACTOligometastatic prostate cancer is a term that is most often used to refer to limited sites of disseminated tumor growth following primary radical prostatectomy (RP) or radiotherapy (RT), while de novo oligometastatic is a term that is used to refer to prostate tumors that have disseminated to limited sites before definitive treatment. In patients with de novo oligometastatic prostate cancer, treatment planning must thus consider the need to manage the primary tumor and the associated distant lesions. Traditionally, resectio...
Source: Technology in Cancer Research and Treatment - December 18, 2023 Category: Cancer & Oncology Authors: Yuan Tian Yifeng Mao Zhizhong Tang Mingqiu Hu Source Type: research

Oncological Applications of Quantum Machine Learning
Conclusion: These studies revealed that integrating quantum science with ML can significantly improve patient care and clinical outcomes. Future studies should explore the integration of QC and ML and the development of novel algorithms to enhance cancer prognosis, diagnosis, and treatment planning.PMID:38105500 | PMC:PMC10729620 | DOI:10.1177/15330338231215214 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - December 18, 2023 Category: Cancer & Oncology Authors: Milad Rahimi Farkhondeh Asadi Source Type: research

Current Controversy and Developments Regarding the Cytoreductive Prostatectomy for Oligometastatic Prostate Cancer
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231216011. doi: 10.1177/15330338231216011.ABSTRACTOligometastatic prostate cancer is a term that is most often used to refer to limited sites of disseminated tumor growth following primary radical prostatectomy (RP) or radiotherapy (RT), while de novo oligometastatic is a term that is used to refer to prostate tumors that have disseminated to limited sites before definitive treatment. In patients with de novo oligometastatic prostate cancer, treatment planning must thus consider the need to manage the primary tumor and the associated distant lesions. Traditionally, resectio...
Source: Technology in Cancer Research and Treatment - December 18, 2023 Category: Cancer & Oncology Authors: Yuan Tian Yifeng Mao Zhizhong Tang Mingqiu Hu Source Type: research

Oncological Applications of Quantum Machine Learning
Conclusion: These studies revealed that integrating quantum science with ML can significantly improve patient care and clinical outcomes. Future studies should explore the integration of QC and ML and the development of novel algorithms to enhance cancer prognosis, diagnosis, and treatment planning.PMID:38105500 | DOI:10.1177/15330338231215214 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - December 18, 2023 Category: Cancer & Oncology Authors: Milad Rahimi Farkhondeh Asadi Source Type: research

Unraveling the Sweet Secrets of HCC: Glucometabolic Rewiring in Hepatocellular Carcinoma
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231219434. doi: 10.1177/15330338231219434.ABSTRACTHepatocellular carcinoma (HCC) is the primary form of liver cancer. It causes ∼ 800 000 deaths per year, which is expected to increase due to increasing rates of obesity and metabolic dysfunction associated steatotic liver disease (MASLD). Current therapies include immune checkpoint inhibitors, tyrosine kinase inhibitors, and monoclonal antibodies, but these therapies are not satisfactorily effective and often come with multiple side effects and recurrences. Metabolic reprogramming plays a significant role in HCC progressi...
Source: Technology in Cancer Research and Treatment - December 12, 2023 Category: Cancer & Oncology Authors: Sheraz Ahmad Bhat Zeenat Farooq Hagar Ismail Irene Corona-Avila Md Wasim Khan Source Type: research

Unraveling the Sweet Secrets of HCC: Glucometabolic Rewiring in Hepatocellular Carcinoma
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231219434. doi: 10.1177/15330338231219434.ABSTRACTHepatocellular carcinoma (HCC) is the primary form of liver cancer. It causes ∼ 800 000 deaths per year, which is expected to increase due to increasing rates of obesity and metabolic dysfunction associated steatotic liver disease (MASLD). Current therapies include immune checkpoint inhibitors, tyrosine kinase inhibitors, and monoclonal antibodies, but these therapies are not satisfactorily effective and often come with multiple side effects and recurrences. Metabolic reprogramming plays a significant role in HCC progressi...
Source: Technology in Cancer Research and Treatment - December 12, 2023 Category: Cancer & Oncology Authors: Sheraz Ahmad Bhat Zeenat Farooq Hagar Ismail Irene Corona-Avila Md Wasim Khan Source Type: research

Unraveling the Sweet Secrets of HCC: Glucometabolic Rewiring in Hepatocellular Carcinoma
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231219434. doi: 10.1177/15330338231219434.ABSTRACTHepatocellular carcinoma (HCC) is the primary form of liver cancer. It causes ∼ 800 000 deaths per year, which is expected to increase due to increasing rates of obesity and metabolic dysfunction associated steatotic liver disease (MASLD). Current therapies include immune checkpoint inhibitors, tyrosine kinase inhibitors, and monoclonal antibodies, but these therapies are not satisfactorily effective and often come with multiple side effects and recurrences. Metabolic reprogramming plays a significant role in HCC progressi...
Source: Technology in Cancer Research and Treatment - December 12, 2023 Category: Cancer & Oncology Authors: Sheraz Ahmad Bhat Zeenat Farooq Hagar Ismail Irene Corona-Avila Md Wasim Khan Source Type: research

Unraveling the Sweet Secrets of HCC: Glucometabolic Rewiring in Hepatocellular Carcinoma
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231219434. doi: 10.1177/15330338231219434.ABSTRACTHepatocellular carcinoma (HCC) is the primary form of liver cancer. It causes ∼ 800 000 deaths per year, which is expected to increase due to increasing rates of obesity and metabolic dysfunction associated steatotic liver disease (MASLD). Current therapies include immune checkpoint inhibitors, tyrosine kinase inhibitors, and monoclonal antibodies, but these therapies are not satisfactorily effective and often come with multiple side effects and recurrences. Metabolic reprogramming plays a significant role in HCC progressi...
Source: Technology in Cancer Research and Treatment - December 12, 2023 Category: Cancer & Oncology Authors: Sheraz Ahmad Bhat Zeenat Farooq Hagar Ismail Irene Corona-Avila Md Wasim Khan Source Type: research

Unraveling the Sweet Secrets of HCC: Glucometabolic Rewiring in Hepatocellular Carcinoma
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231219434. doi: 10.1177/15330338231219434.ABSTRACTHepatocellular carcinoma (HCC) is the primary form of liver cancer. It causes ∼ 800 000 deaths per year, which is expected to increase due to increasing rates of obesity and metabolic dysfunction associated steatotic liver disease (MASLD). Current therapies include immune checkpoint inhibitors, tyrosine kinase inhibitors, and monoclonal antibodies, but these therapies are not satisfactorily effective and often come with multiple side effects and recurrences. Metabolic reprogramming plays a significant role in HCC progressi...
Source: Technology in Cancer Research and Treatment - December 12, 2023 Category: Cancer & Oncology Authors: Sheraz Ahmad Bhat Zeenat Farooq Hagar Ismail Irene Corona-Avila Md Wasim Khan Source Type: research

Identifying TYMP as an Immune Prognostic Marker in Clear Cell Renal Cell Carcinoma
CONCLUSIONS: Patient survival is poor and immune cell infiltration is abnormal when TYMP is highly expressed in ccRCC, suggesting that ccRCC patients could benefit from using TYMP as a molecular diagnostic and therapeutic target.PMID:38043946 | PMC:PMC10695089 | DOI:10.1177/15330338231194555 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - December 3, 2023 Category: Cancer & Oncology Authors: Shao-An Chen Jun-Peng Zhang Ning Wang Ji Chen Source Type: research

Identifying TYMP as an Immune Prognostic Marker in Clear Cell Renal Cell Carcinoma
CONCLUSIONS: Patient survival is poor and immune cell infiltration is abnormal when TYMP is highly expressed in ccRCC, suggesting that ccRCC patients could benefit from using TYMP as a molecular diagnostic and therapeutic target.PMID:38043946 | PMC:PMC10695089 | DOI:10.1177/15330338231194555 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - December 3, 2023 Category: Cancer & Oncology Authors: Shao-An Chen Jun-Peng Zhang Ning Wang Ji Chen Source Type: research

Identifying TYMP as an Immune Prognostic Marker in Clear Cell Renal Cell Carcinoma
CONCLUSIONS: Patient survival is poor and immune cell infiltration is abnormal when TYMP is highly expressed in ccRCC, suggesting that ccRCC patients could benefit from using TYMP as a molecular diagnostic and therapeutic target.PMID:38043946 | PMC:PMC10695089 | DOI:10.1177/15330338231194555 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - December 3, 2023 Category: Cancer & Oncology Authors: Shao-An Chen Jun-Peng Zhang Ning Wang Ji Chen Source Type: research

Identifying TYMP as an Immune Prognostic Marker in Clear Cell Renal Cell Carcinoma
CONCLUSIONS: Patient survival is poor and immune cell infiltration is abnormal when TYMP is highly expressed in ccRCC, suggesting that ccRCC patients could benefit from using TYMP as a molecular diagnostic and therapeutic target.PMID:38043946 | PMC:PMC10695089 | DOI:10.1177/15330338231194555 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - December 3, 2023 Category: Cancer & Oncology Authors: Shao-An Chen Jun-Peng Zhang Ning Wang Ji Chen Source Type: research

Identifying TYMP as an Immune Prognostic Marker in Clear Cell Renal Cell Carcinoma
CONCLUSIONS: Patient survival is poor and immune cell infiltration is abnormal when TYMP is highly expressed in ccRCC, suggesting that ccRCC patients could benefit from using TYMP as a molecular diagnostic and therapeutic target.PMID:38043946 | PMC:PMC10695089 | DOI:10.1177/15330338231194555 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - December 3, 2023 Category: Cancer & Oncology Authors: Shao-An Chen Jun-Peng Zhang Ning Wang Ji Chen Source Type: research

Identifying TYMP as an Immune Prognostic Marker in Clear Cell Renal Cell Carcinoma
CONCLUSIONS: Patient survival is poor and immune cell infiltration is abnormal when TYMP is highly expressed in ccRCC, suggesting that ccRCC patients could benefit from using TYMP as a molecular diagnostic and therapeutic target.PMID:38043946 | PMC:PMC10695089 | DOI:10.1177/15330338231194555 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - December 3, 2023 Category: Cancer & Oncology Authors: Shao-An Chen Jun-Peng Zhang Ning Wang Ji Chen Source Type: research